UK MHRA Finds Labs Releasing Unreliable Data Due To Pressure From Pharma
A UK regulator with the MHRA is concerned that bioanalytical laboratories are not being given enough time to do their job properly by drug companies under pressure to ensure their clinical trials remain on schedule.
You may also be interested in...
Adaptive clinical trials offer several benefits, but they require effective management to be successful, says a senior inspector at the UK’s medicines regulator.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.